What You Should Know: - COTA, Inc., an oncology real-world data and analytics company and the University of Chicago Medicine announced a research collaboration agreement to investigate racial disparities of care in multiple myeloma to better understand differences in the diagnosis, treatment patterns, and outcomes of patients with this type of cancer. - Multiple myeloma is the second-most-common hematologic malignancy, with an estimated 34,920 new cases and 12,410 deaths expected to occur
Read More
COTA
COTA Lands $34M to Drive Innovation in Oncology Using Real-World Data
What You Should Know: - COTA, Inc., a healthcare technology company that uses real-world data to bring clarity to cancer care, has secured $34M in funding. - Access to over one million patient data records and additional funding support enhanced real-world data and analytics services in oncology. COTA, Inc., a Boston, MA-based healthcare technology company that uses real-world data to bring clarity to cancer care, today announced it has raised $34 million in Series D funding led by
Read More
FDA Extends RCA With COTA to Explore COVID’s Effect on Cancer
What You Should Know: - The FDA just extended its research collaboration agreement (RCA) with COTA, specifically looking at how COVID-19 is affecting cancer. - With this expanded agreement, COTA and the FDA will use real-world data to explore the impact of COVID-19 and the pandemic on cancer treatment, with the opportunity to expand into other oncology questions in the future. COTA, Inc., a healthcare technology company that uses real-world data to bring clarity to cancer care,
Read More
Mission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics Platform
What You Should Know: - Mission Bio raises $70 million in Series C funding led by Novo Growth to accelerate the development of cancer therapies with single-cell multi-omics. - Mission Bio’s Tapestri Platform, the first single-cell platform capable of detecting DNA and protein changes simultaneously, gives a profound insight into the mutations that drive disease to accelerate the development of novel treatments and save patient lives. Mission Bio, Inc., a South San Francisco,
Read More
2020 MedTech Breakthrough Award Winners Announced
What You Should Know: - MedTech Breakthrough announces 2020 MedTech Breakthrough Award Winners that recognizes the top companies, people, platforms, and products in the health, fitness, and medical technology industries today. - The 2020 MedTech Breakthrough Awards program is open to all individuals, companies, and organizations involved in producing digital health and medical technology products and services. MedTech Breakthrough, a market intelligence organization that recognizes
Read More
Cota Lands $40M to Accelerate Value-based Precision Medicine
Cota, a NYC-based healthcare data and analytics company bridging precision medicine to population health has raised $40 million in Series C funding led by QVIA and was contributed to by EW Healthcare Partners. Memorial Sloan Kettering Cancer Center also participated in the round, along with existing Cota investors which include, Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings.The funding will go towards rapidly scaling its
Read More
Cota Partners with Miami Cancer Institute to Fuel Personalized Cancer Treatment
Cota, a healthcare data and analytics company bridging precision medicine to population health has announced their latest collaboration with Baptist Health South Florida to advance cancer treatment and clinical research at the new Miami Cancer Institute (MCI). The partnership will further support the organization’s initiative of precision medicine, improve care delivery and ensure the most effective treatment for every type of cancer.MCI will leverage Cota’s Provider Solution to identify
Read More
Memorial Sloan Kettering, Cota Partner to Advance Personalized Cancer Treatment
In 2011, Cota, a healthcare data and analytics company bridging precision medicine and population health, was founded by doctors for doctors. Over the past six years, the start-up has moved beyond precision medicine as a goal to a reality, and just this past year, have secured a multi-year collaboration with Novartis towards breast cancer and recruited top thought leaders in the space, like former Deputy Chief Health Officer at IBM Watson, Dr. Andrew Norden.Today, Cota announced their latest
Read More
Cota, Hackensack Meridian Integrates “Digital Map of Cancer” Into Epic EHR
Hackensack Meridian Health (HMH), a New Jersey-based integrated health care system and Cota, a leading data and technology platform for value-based precision medicine has teamed up to improve clinical and cost outcomes for cancer patients.As part of the partnership, HMH will integrate Cota Nodal Addresses™ (CNAs) directly into its Epic EHR to help support decision-making by oncologists at the point of care. CNAs are generated by a unique, patented digital data classification methodology that
Read More
Big Data Cancer Platform COTA Secures $3.7M in Funding from Insurer
Big data cancer platform COTA closes $3.7M of planned $7M Series A funding round to make value-based cancer care delivery and reimbursement a reality. The promise of value-based care and big data insights in healthcare are undeniable. But few have found a way to integrate it in a real-life setting and obtain the consensus of payers, providers, patients, technology partners etc. COTA, which today closed $3.7M in Series A funding from Horizon Healthcare Services, Inc. , is changing that status
Read More
